OVERVIEW

Economic and Clinical Outcomes Assessment of Immuno-Oncology Agents: A Guide for Payer Decision Makers Web Activity is organized by Impact Education, LLC, Postgraduate Institute for Medicine (PIM).

Release Date: August 31, 2020
Expiration Date: February 28, 2022
Estimated Time to Complete Activity: 1.0 hour

Accreditation:
Physician Continuing Medical Education:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education:
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Statement of Need/Program Overview:
The advent and rapid escalation of targeted cancer therapies has led to the emergence of sophisticated immuno-oncology agents. However, the historically high cost of these agents has compelled payers to initiate strategies to control utilization and manage costs. Because of the explosive growth of this category and their corresponding budgetary impact, healthcare decision makers (HCDMs) and managed care professionals require education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments. Furthermore, given increased focus on value-based benefit design, utilization management, and payer-led clinical interventions to address shortfalls in oncology practice, managed care stakeholders also have a need for information to effectively address the evolving paradigm of cancer treatment. This symposium will provide HCDMs and managed care professionals with the required education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments.

Educational Objectives:
At the conclusion of this activity, participants should be able to demonstrate improved ability to:
• Characterize the role of the immune system in immunosurveillance and elimination of malignant cell lines
• Explain the mechanisms of action of novel immuno-oncology agents such as PD-1 and PD-L1 inhibitors and CAR-T therapies
• Describe key outcomes measures in immuno-oncology and the importance of cumulative assessment of outcomes
• Apply comprehensive analyses of emerging clinical trial data for checkpoint inhibitors and CAR-T therapies
• Illustrate current and proposed payer initiatives for the funding and management of checkpoint inhibitors and CAR-T therapies